United Kingdom Molecular Diagnostics Market is anticipated to grow significantly
in the forecast period, 2024-2028. Molecular
diagnostics has emerged as a game-changer in the field of healthcare,
transforming the way diseases are diagnosed and managed. The United Kingdom
(UK) has been at the forefront of adopting molecular diagnostic technologies,
leveraging their potential to improve patient outcomes and streamline
healthcare delivery. The application of molecular biology methods to the study
of human diseases, such as cancer, inherited disorders, and infectious
diseases, is known as molecular diagnostics. Molecular diagnostics research
focuses on genomic and proteomic analysis to identify disease biomarkers, improve
diagnostic assays, and ultimately discover new treatments and potential cures.
The fundamental methods of molecular biology, such as nucleic acid isolation
and quantification, PCR amplification, sequencing, and STR analysis, are
employed in molecular diagnostic applications. The rising incidence of chronic
diseases, such as cancer, cardiovascular disorders, and infectious diseases,
has necessitated the development of accurate and efficient diagnostic tools.
Molecular diagnostics offers the ability to detect diseases at an early stage,
enabling prompt treatment interventions, leading to the growth of the United
Kingdom Molecular Diagnostics Market. Significant advancements in molecular
biology, genetic sequencing, and bioinformatics have facilitated the development
of innovative diagnostic techniques. Next-generation sequencing (NGS),
polymerase chain reaction (PCR), and microarray technologies have
revolutionized the detection and analysis of genetic and molecular alterations.
In addition, molecular diagnostics plays a pivotal role in the era of
personalized medicine. By analyzing an individual's genetic makeup, healthcare
providers can tailor treatment plans and therapies to suit their specific
needs. This approach enhances treatment effectiveness and minimizes adverse
effects, hence augmenting the growth of the United Kingdom Molecular
Diagnostics Market. The demand for rapid and decentralized diagnostic testing
has led to the development of Point-of-Care Testing devices for molecular
diagnostics. These handheld devices allow for quick and accurate diagnosis at
the patient's bedside, reducing the turnaround time for test results and
enabling timely clinical decisions. Collaborations between academic
institutions, government bodies, and industry players have fostered research
and development in molecular diagnostics. These partnerships have led to the
translation of scientific discoveries into clinical applications, accelerating
the availability of novel diagnostic tools. With an aging population comes an
increased prevalence of age-related diseases and conditions. Chronic diseases
such as cardiovascular disorders, cancer, diabetes, and neurodegenerative
disorders are becoming more common among the elderly. Prompt and accurate
diagnosis of these conditions is crucial for effective treatment and
management. molecular diagnostics play a vital role in identifying diseases at
an early stage, monitoring disease progression, and guiding personalized
treatment decisions.
Growing
Prevalence of Chronic Diseases
With
the rising prevalence of chronic disease, the demand for effective molecular
diagnostics in the United Kingdom has witnessed a notable surge. Chronic
diseases have become a leading cause of morbidity and mortality worldwide, and
the United Kingdom is no exception. Factors such as an aging population,
sedentary lifestyles, unhealthy dietary habits, and environmental factors
contribute to the increasing prevalence of chronic conditions. According to the
National Health Service (NHS), cancer and cardiovascular diseases remain the
two most common causes of death in the United Kingdom. Additionally, the
emergence of drug-resistant infections and the rising incidence of genetic
disorders have further amplified the need for accurate and personalized
diagnostics. This is expected to propel the growth of the United Kingdom
Molecular Diagnostics Market. The United Kingdom molecular diagnostics market
is witnessing robust growth due to the increasing demand for advanced
diagnostic techniques. Technological advancements, such as next-generation
sequencing (NGS), polymerase chain reaction (PCR), and microarray technologies,
have revolutionized the field. These technologies allow for high-throughput
analysis, improved sensitivity, and specificity, making them ideal for early disease
detection and monitoring, thus augmenting the growth of the United Kingdom
Molecular Diagnostics Market.
Download Free Sample Report
Technological Advancements Propel United Kingdom Molecular
Diagnostics Market
One of the key technological advancements driving
the United Kingdom's molecular diagnostics market is the advent of
next-generation sequencing (NGS). NGS has revolutionized genomic research and
diagnostics by enabling rapid and cost-effective sequencing of DNA and RNA.
This technology has significantly expanded the understanding of genetic
variations and their role in diseases, allowing for more accurate diagnoses and
personalized treatment plans. NGS has found applications in various areas,
including oncology, infectious diseases, and genetic disorders, and has become an
integral part of molecular diagnostic laboratories across the country.
Another significant technological advancement is
the development of innovative molecular testing platforms. These platforms
combine automation, miniaturization, and high-throughput capabilities, allowing
for faster and more efficient testing. For example, polymerase chain reaction
(PCR) machines have evolved from conventional thermal cyclers to real-time PCR
systems, which enable the quantification of target molecules in real-time. These
advanced platforms offer improved sensitivity, specificity, and turnaround
time, making them invaluable tools for diagnosing infectious diseases,
monitoring treatment responses, and detecting genetic mutations.
The United Kingdom has also embraced digital
pathology, which involves the digitization and analysis of histopathology
slides. Digital pathology systems enable pathologists to access and review
high-resolution digital images of tissue samples remotely, facilitating
collaboration, second opinions, and archival purposes. This technology has the
potential to improve diagnostic accuracy, reduce turnaround time, and enhance
patient care. Additionally, the integration of artificial intelligence (AI)
algorithms with digital pathology platforms holds great promise in automating
image analysis and aiding pathologists in detecting subtle patterns or
abnormalities that may be missed by the human eye.
According to the Office for National Statistics, in
2021, the total current healthcare expenditure increased by 7.1% in real terms
compared to 10.0% in 2020, after accounting for the effects of inflation on the
economy as a whole.
Increase in Demand for Genetic Testing Drives
United Kingdom Molecular Diagnostics Market
In recent years, the United Kingdom has witnessed a
significant increase in demand for genetic testing, contributing to the rapid
growth of the molecular diagnostics market. This surge in demand can be
attributed to several factors, including advancements in technology, rising
awareness of genetic diseases, and a shift towards personalized medicine. One
of the key drivers of increased demand for genetic testing in the United Kingdom
is the rapid advancements in technology. The field of molecular diagnostics has
witnessed remarkable progress in recent years, particularly in sequencing
technologies such as next-generation sequencing (NGS). NGS has revolutionized
genetic testing by enabling the simultaneous analysis of multiple genes and
providing comprehensive insights into an individual's genetic makeup. The
declining costs of sequencing technologies have made genetic testing more
accessible and affordable, thus encouraging its adoption among healthcare
professionals and individuals seeking to understand their genetic
predispositions, leading to the growth of the United Kingdom Molecular
Diagnostics Market.
Recent Developments
- In July
2022, Siemens Healthineers unveiled The Atellica CI 1900 Analyzer at the
American Association for Clinical Chemistry 2022. It is a clinical
chemistry and immunoassay testing system, serving as a lower volume
variant of Siemens Healthineers' currently marketed Atellica clinical
chemistry and immunoassay testing solution. The system has the capacity to
perform over 25,000 immunoassay tests and over 250,000 clinical chemistry
tests annually. According to Siemens Healthineers, the new analyzer can be
used as a stand-alone system in hub-and-spoke configurations connected to
integrated delivery networks.
Mergers
& Acquisitions
- In March 2020, Thermo Fisher
Scientific and Johnson & Johnson's Janssen Biotech announced a
collaborative effort to co-develop a companion diagnostic (CDx) in the field
of oncology. As part of this agreement, Thermo Fisher and Janssen's
R&D scientists will collaborate to validate biomarkers for use with
Thermo Fisher's Oncomine DX target test. The aim is to identify
variant-positive patients for enrollment into clinical trials focusing on
non-small cell lung cancer (NSCLC).
- In March 2023, Mylab Discovery
Solutions and DnaNudge announced a strategic alliance to develop advanced
molecular diagnostic tools for the early detection of diabetic foot ulcers
and other serious illnesses.
Market
Segmentation
The United Kingdom Molecular Diagnostics Market is
categorized into different segments, including Component, Technology,
Application, End User, Region and Company. In terms of Component, it is divided
into Instruments, Reagents, Software, and Services. The Technology segment
comprises PCR, DNA Sequencing, Hybridization, Microarray, INAAT, and others.
The Application segment includes Oncology, Infectious Disease Testing, Genetic
Testing, and others. End User categories are Hospitals & Clinics,
Diagnostic Laboratories, and others. The market is further segmented by region,
including Scotland, South-East, London, South-West, East-Anglia, Yorkshire
& Humberside, and East Midlands.
Company
Profiles
Johnson & Johnson, Abbott Laboratories Ltd., Siemens
Healthineers AG, Hologic Inc., Qiagen N.V., Becton, Dickinson and Company Ltd, bioMérieux
SA, Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche
Ltd are some of the key players in the United Kingdom Molecular Diagnostics market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2021
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million and CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast,
company shares, competitive landscape, growth factors, and trends
|
|
Segments covered
|
Component
Technology
Application
End User
Region
|
|
Country scope
|
Scotland,
South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and
East Midlands
|
|
Key companies
profiled
|
Johnson & Johnson, Abbott Laboratories Ltd., Siemens Healthineers
AG, Hologic Inc., Qiagen N.V., Becton, Dickinson and Company Ltd, bioMérieux
SA, Agilent Technologies Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La
Roche Ltd.
|
|
Customization scope
|
10% free report customization with purchase.
Addition or alteration to country, regional & segment scope.
|
|
Pricing and
purchase options
|
Avail customized
purchase options to meet your exact research needs.
|
|
Delivery Format
|
PDF and Excel through Email (We can also provide the
editable version of the report in PPT/Word format on special request)
|
Report
Scope:
In
this report, United Kingdom Molecular Diagnostics Market has been segmented into
the following categories, in addition to the industry trends, which have also
been detailed below:
- United Kingdom Molecular Diagnostics Market,
By Component:
- Instruments
- Reagents
- Software
- Services
- United Kingdom Molecular Diagnostics Market,
By Technology:
- PCR
- DNA Sequencing
- Hybridization
- Microarray
- INAAT
- Others
- United Kingdom Molecular Diagnostics Market,
By Application
- Oncology
- Infectious Disease Testing
- Genetic Testing
- Others
- United Kingdom Molecular Diagnostics Market,
By End User:
- Hospitals & Clinics
- Diagnostic Laboratories
- Others
- United Kingdom Molecular Diagnostics Market,
By Region:
- Scotland
- South-East
- London
- South-West
- East-Anglia
- Yorkshire & Humberside
- East Midlands
Competitive
landscape
Company
Profiles: Detailed
analysis of the major companies in United Kingdom Molecular Diagnostics market.
Available
Customizations:
With
the given market data, TechSci Research offers customizations according to a
company’s specific needs. The following customization options are available for
the report:
Company
Information
- Detailed
analysis and profiling of additional market players (up to five).
United
Kingdom Molecular Diagnostics Market is an upcoming report to be released soon.
If you wish an early delivery of this report or want to confirm the date of release,
please contact us at [email protected]